0.31%QQQQ 43.45 
0.48%XLF 21.74 3.62%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
GAITHERSBURG, Md. - Iomai Corp., a vaccine research company, said Thursday it will conduct preclinical trials with Merck & Co. to review uses for its patch which stimulates the immune system.
The deal gives drugmaker Merck an option to negotiate an exclusive license if the patch proves viable.
Iomai said it has data from a trial showing the patch, when used with an influenza vaccine, had a clinically relevant boosting effect on elderly patients' immune systems.
The above adage is well known by precious-metals investors; in fact I used this quote in one of our monthly reports. I recall how many inquiries ...
The review was scathing. "She cannot sing very well," it said. "She is flat a go...
IN THE HEADLINES McCain caps GOP convention vowing 'change is coming' to Washing...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
0.01
